ANVS
Annovis Bio, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Apr 2 ▲ 1 insider buy $1.5M at $2.10
- May 20 ▲ 1 insider buy $142.8K at $1.87
- Jul 8 Roth Capital initiates
- Nov 4 ▼ Annovis Bio filed a preliminary prospectus supplement for an underwr…
- Nov 4 ▼ Annovis Bio disclosed preliminary cash and cash equivalents of appro…
- Nov 4 ▼ Annovis Bio announced a proposed underwritten public offering of com…
- Nov 4 Offering: Annovis Announces Launch of Proposed Public Offering
- Nov 5 ▼ Annovis Bio entered into an underwriting agreement with Canaccord Ge…
- Nov 5 Offering: Annovis Announces Pricing of $21.0 Million Public Offering
- Nov 5 ▼ Annovis Bio priced an underwritten public offering of 19 million sha…
- Nov 5 ▼ Annovis Bio priced a distressed $21M underwritten public offering of…
- Nov 6 ▲ 1 insider buy $5.0M at $0.5000
- Nov 13 New catalyst: subscribers see the details Unlock
Signal stack
Where each data set points today.
- InsidersBULLISH
1 insider bought $6.6M at an average $1.15. No open-market sales. Price is 35% below their cost.
- InstitutionsBULLISH
Q3 2026: 9 added (0 new), 2 trimmed or exited.
- AnalystsBULLISH
9 of 10 rate it Buy or better.
- Short sellersSTEADY
Short interest −6.4% to 5.36M shares. 6.8 days to cover, ≈8.4% of shares.
- TrendDOWNTREND
31% below its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Nov 5.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | TRIM | $934.8K |
| VANGUARD FIDUCIARY TRUST CO | ADD | $284.8K |
| MORGAN STANLEY | DOUBLED | $253.2K |
| UBS Group AG | DOUBLED | $145.5K |
| STATE STREET CORP | ADD | $133.8K |
| JPMORGAN CHASE & CO | ADD | $25.9K |
| OSAIC HOLDINGS, INC. | DOUBLED | $8.4K |
| PNC FINANCIAL SERVICES GROUP, INC. | DOUBLED | $3.8K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
10 analysts| Date | Firm | Rating |
|---|---|---|
| Nov 16, 2026 | 🔒 Fresh data, subscribers only REITERATE | |
| Aug 28, 2026 | Roth Capital MAINTAIN | Buy |
| Aug 18, 2026 | Canaccord Genuity MAINTAIN | Buy |
| Jul 8, 2026 | Roth Capital INITIATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Hoffman Michael B Director Nov 6, 2026 | BUY | 5,000,000 sh |
Hoffman Michael B Director Nov 6, 2026 | BUY | $5.0M |
Hoffman Michael B Director May 20, 2026 | BUY | $104.4K |
Hoffman Michael B Director May 20, 2026 | BUY | $33.9K |
Hoffman Michael B Director May 20, 2026 | BUY | $4.5K |
Hoffman Michael B Director Apr 2, 2026 | BUY | $1.5M |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
15 filings · 4 press releases · 0 bullish · 8 bearish · 2 mixed · 5 neutral- NEUTRAL PRESS-RELEASENov 13, 2026
Annovis Bio reported a Q3 2026 net loss of $0.22 per share, narrower than the $0.37 loss in Q3…
The March 2027 DUET-AD topline data is the primary catalyst; the $21M raise provides runway to that event but leaves no margin for delay. Monitor enrollment close of OLE-PD (Jan 29, 2027) and any…
- BEARISH 8-KNov 5, 2026
Annovis Bio entered into an underwriting agreement with Canaccord Genuity for a public offering of…
The offering closes November 6, 2026. Monitor for the company's ability to continue as a going concern given the rapid cash burn and delisting risk. The warrants have a five-year term and a $1.00…
- BEARISH 424B5Nov 5, 2026
Annovis Bio priced an underwritten public offering of 19 million shares of common stock (or…
The offering provides a cash runway extension but does not resolve the structural going-concern and delisting risks. Monitor the company's ability to regain NYSE compliance within 9 months and the…
- BEARISH PRESS RELEASENov 5, 2026
Annovis Bio priced a distressed $21M underwritten public offering of 19M common shares (plus 2M…
The offering provides near-term cash but at extreme dilution; watch for the final prospectus supplement for net proceeds and any further financing needs. The NYSE compliance plan deadline is within…
All ANVS filing & press-release reports (19)
- PRESS-RELEASE reportNov 13, 2026
- 8-K reportNov 5, 2026
- 424B5 reportNov 5, 2026
- PRESS-RELEASE reportNov 5, 2026
- 424B5 reportNov 4, 2026
- PRESS-RELEASE reportNov 4, 2026
- 8-K reportNov 4, 2026
- 8-K reportOct 30, 2026
- 8-K reportOct 19, 2026
- SC 13G/A reportOct 15, 2026
- DEFA14A reportOct 7, 2026
- 8-K reportJul 9, 2026
- 424B5 reportMay 20, 2026
- 424B5 reportMay 19, 2026
- 8-K reportMay 15, 2026
- PRESS-RELEASE reportMay 15, 2026
- PRESS-RELEASE reportApr 10, 2026
- PRESS-RELEASE reportMar 19, 2026
- PRESS-RELEASE reportMar 16, 2026